全球医药领先品牌_肿瘤特效药_抗癌新药_靶向药物_全球医药咨询-【健康光环全球医药】 -

Medical News

What diseases can Upatinib be used for? Which patients are suitable for use?

2026-02-09 05:42:31

Upatinib (Rift) ®） As an oral JAK inhibitor, it has been approved for various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, etc. The target population is mainly moderate to severe patients, especially suitable for adults who have insufficient response to traditional treatment, need oral convenience, or have poor injection compliance.

Check Details

The efficacy of Eltrombopag

2026-02-09 04:16:06

As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.

Check Details